Stealth BioTherapeutics Corp MITO

Set alert

Price alert · MITO

All alert types
0.32 0.00 0.00%

At close · Nov 15

0.32 Day range 0.33

52-week range unavailable

Open
0.3242
Prev close
0.32
Mkt cap
0
Vol
1.30M
Avg vol
0
EPS
0.00
P/E
0.00
Div yield
0.00%
More statistics
Low
0.32
High
0.33
Forward P/E
-6.40
Beta
1.46
Short ratio
1.77
Inst. own
7.86%
Dividend
0.00
Ex-div date
Earnings
Nov 17, 2022
50-d avg
0.315554
200-d avg
0.368184
1y target
1.77

1M chart

Chart tools
Interval

Chart is warming up

The one-month price history for MITO has not been loaded yet. Try again in a moment.

Analyst view

Consensus: buy

Buy
Price target (mean) 1.77 +453.1% upside
Target (low)
1.50
Target (mean)
1.77
Target (high)
2.05

Recommendation trend

  • 1 month ago 1
  • 2 months ago 1

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

MITO analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter-0.02-0.03 – -0.01-0.01-100.0%00.0%2
Next quarter-0.01-0.01 – -0.01-0.03+66.7%00.0%2
Current year-0.06-0.07 – -0.05-0.08+25.0%00.0%2
Next year-0.05-0.06 – -0.04-0.06+16.7%00.0%2

Upgrades and downgrades

The latest rating changes

MITO analyst upgrades and downgrades
DateFirmActionFromTo
May 23, 2022HC Wainwright & Co.Maintained—Buy
Jul 1, 2021Maxim GroupInitiated—Buy
Apr 3, 2020NomuraMaintained—Buy
Apr 2, 2020HC Wainwright & Co.UpgradeNeutralBuy
Dec 23, 2019H.C. WainwrightDowngradeBuyNeutral
Sep 27, 2019Cantor FitzgeraldInitiated—Overweight
Jun 18, 2019H.C. WainwrightInitiated—Buy
Mar 12, 2019NomuraInitiated—Buy
Mar 12, 2019BMO CapitalInitiated—Outperform